The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...

Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer ...

The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...

The patent US12048608B2 describes an innovative oral appliance designed to enhance dental treatment through adjustable features that promote mandibular advancement. The appliance consists of an upper ...

According to GlobalData’s company profile on Laurus Labs, Peptide pharmacophores was a key innovation area identified from patents. Laurus Labs's grant share as of July 2024 was 62%. Grant share is ...

UCB has received US FDA approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions.

According to GlobalData’s company profile on Agile Therapeutics, was a key innovation area identified from patents. Agile Therapeutics's grant share as of July 2024 was 40%. Grant share is based on ...

According to GlobalData’s company profile on Telesis Bio, was a key innovation area identified from patents. Telesis Bio's grant share as of July 2024 was 62%. Grant share is based on the ratio of ...

The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...

The European Commission (EC) has conditionally approved Ipsen ’s Iqirvo (elafibranor) for the treatment of primary biliary ...

Pancreatic cancer is resistant to conventional therapies, but cutting-edge research may improve survival rates and patient ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.